These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 19566116

  • 1. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM.
    Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
    [Abstract] [Full Text] [Related]

  • 2. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE, Nicholls AJ, Kamm BR.
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE, Tett SE.
    Clin Pharmacokinet; 2007 Jun; 46(1):13-58. PubMed ID: 17201457
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 6. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report.
    Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, Oellerich M, MMF Creeping Creatinine Study Group.
    Ther Drug Monit; 2001 Dec; 23(6):717-21. PubMed ID: 11802109
    [Abstract] [Full Text] [Related]

  • 7. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication.
    Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM.
    Ther Drug Monit; 2002 Oct; 24(5):598-606. PubMed ID: 12352931
    [Abstract] [Full Text] [Related]

  • 9. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [Abstract] [Full Text] [Related]

  • 10. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 11. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [Abstract] [Full Text] [Related]

  • 12. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 13. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 15. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 16. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.
    Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.
    Nephrol Dial Transplant; 2009 Jul; 24(7):2269-76. PubMed ID: 19357111
    [Abstract] [Full Text] [Related]

  • 17. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [Abstract] [Full Text] [Related]

  • 18. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM.
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [Abstract] [Full Text] [Related]

  • 20. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.
    Jiao Z, Zhong JY, Zhang M, Shi XJ, Yu YQ, Lu WY.
    Eur J Clin Pharmacol; 2007 Jan; 63(1):27-37. PubMed ID: 17093994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.